Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 18;13:946356. doi: 10.3389/fimmu.2022.946356

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Idda, Pitzalis, Lodde, Loizedda, Frau, Lobina, Zoledziewska, Virdis, Delogu, Marini, Mingoia, Masala, Lorefice, Fronza, Carmagnini, Carta, Pilotto, Castiglia, Chessa, Uzzau, Farina, Solla, Steri, Devoto, Fiorillo, Floris, Zarbo, Cocco and Cucca

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Post-vaccination SARS-CoV-2 anti-S antibody response by disease- modifying therapy (DMT) in MS patients negative for anti-N antibodies. (A) Antibody response to SARS-CoV-2 vaccination by DMT in MS patients six month after SARS-CoV-2 vaccination (T2). (B) Antibody response one month after booster (T3) by DMT in MS patients. Results are reported as boxplots, showing the median value (in bold) and the quartiles as box limits; whiskers at the top and bottom sides represent the overall maximum value and the overall minimum value, respectively. Data outside boxes and whiskers represent the outliers of the distribution. (**P<0.01; ***<0.001). (UNT, untreated; ALEM, alemtuzumab; IFN, interferon; GA, glatiramer acetate; DMF, dimethyl fumarate; NAT, natalizumab; CLA, cladribine; TER,terifluomide; AZA, azathioprine; FTY, fingolimod; RTX, rituximab; OCR, ocrelizumab).